1.09k likes | 1.31k Views
An Assessment of the Accutane (Isotretinoin) Pregnancy Prevention Program. Allen A. Mitchell, M.D. Carla Van Bennekom, R.N., M.P.H. Carol Louik, Sc.D. Slone Epidemiology Unit Boston University School of Public Health. Pregnancy Prevention Program (PPP):. Introduced in fall, 1988
E N D
An Assessment of theAccutane (Isotretinoin)Pregnancy Prevention Program Allen A. Mitchell, M.D. Carla Van Bennekom, R.N., M.P.H. Carol Louik, Sc.D. Slone Epidemiology Unit Boston University School of Public Health
Pregnancy Prevention Program (PPP): • Introduced in fall, 1988 • Multi-component program • Aimed at female patients and their physicians • Unprecedented and novel approach
Survey of Accutane Use in Women Sponsored by: Hoffmann-La Roche, Inc. SEU Responsible for: - Design/Protocol - Data Collection - Data Processing - Data Analysis Guidance provided by: Independent Advisory Committee
Paul D. Stolley, M.D., Chair* University of Maryland School of Medicine Baltimore, MD Edward L. Decker, Pharm.D. New England Medical Center Boston, MA Karen McKoy, M.D. Lahey Clinic Burlington, MA Observers: Charlotte Catz, M.D., NICHD John Melski, M.D. Marshfield Clinic Marshfield, WI Peter Pochi, M.D. Boston University School of Medicine Boston, MA Robert S. Stern, M.D. Harvard Medical School Boston, MA José F. Corderó, M.D., CDC Slone Epidemiology UnitAccutane Survey Advisory Committee1988 - 2000 *Dr. Stolley resigned as Committee Chair on July 19, 2000 because he has joined the FDA as a Senior Consultant.
Objectives To assess compliance with the Pregnancy Prevention Program • Awareness of the teratogenic risk • Patient and physician behaviors • Pregnancy rate • Pregnancy outcome • Risk factors for pregnancy
Limitations • No pilot testing • No pre/post comparison • What is “success”? • Survey itself is an intervention • Voluntary enrollment/? representativeness
Accutane Survey Design
Accutane SurveyTIME PERIOD OF INTEREST(Duration of Follow-up)
To Encourage Enrollment • Multiple/different opportunities • Keep it simple • Provide payment
Enrollment Opportunities 1) Physician-generated • All prescriptions originate with physician • Logistically feasible • Strong incentive
Enrollment Opportunities 2) Toll-free telephone call • Simple • Quick • Familiar
Enrollment Opportunities 3) Package-generated • Unique • Direct to patient • Bypasses physician • May preferentially target women who • were not encouraged by their physician • may be relatively noncompliant • are attracted by payment
Follow-Up Approaches Frequent: During and After Treatment (DAT) Advantage - Avoid recall bias Disadvantage - ? Affect outcome beyond PPP
Follow-Up Approaches Infrequent: After Treatment only (AT) Advantage - Avoids intervention beyond PPP Disadvantage - Potential recall bias
Accutane Survey Results
Accutane SurveyEnrollments: 1989-1999 Cumulative enrollments through 6/30/00: >494,000
Follow-Up Rates During and After Treatment (“DAT”) Number to date (6/00): 61,659 1/89 - 12/94 (telephone) 32,301 Completed Follow-Up: Tx start 98% Tx middle 98% 6 mos.`p Tx 93%
Follow-Up Rates During and After Treatment (“DAT”) 1/95 - 6/00 (mail) 29,358 Completed Follow-Up: Tx start 98% Tx middle 98% 6 mos.`p Tx 97%
Follow-Up Rates After Treatment (“AT”) Number to date (6/00): 433,256 Completed Follow-Up: 6 mos.`p Tx 80-86%
Accutane Survey Results: Demographics
Age1/89 – 6/00(n=494,915) Mean (years) 25.6 Median (years) 24
Pregnancy Risk Categories(at DAT 1)1/95 – 6/00(n=28,016) 3% Hysterectomy/postmenopausal 57% Not sexually active 40% Sexually active
Pregnancy Risk Categories(at DAT 1)1/95 – 6/00(n=28,016) 57% Not sexually active: Using birth control 44% Not using birth control 56% 100% 40% Sexually active: Using birth control 98% Not using birth control 2% 100%
Accutane Survey Results: Women’s Knowledge
Receipt of PPP Information1/95 – 6/00(n=28,386) Patient brochure 92% True/false test 42% Birth Control brochure 53%
Knowledge of Accutane Risk1/95 – 6/00(n=28,386) May cause miscarriage 43% May cause birth defects 99%
Accutane Survey Results: Compliance
Compliance with PPP – I1/95 – 6/00(n=28,386) Told to avoid pregnancy 99% Signed consent form 77% Postpone Accutane until pregnancy test 67% Postpone Accutane until next menstrual period 57%
Compliance with Selected Measures of the PPP n=5,108 n=5,157 n=5,206 n=5,047 n=5,283 n=2,585
Compliance with PPP – IIPregnancy Testing1/95 – 6/00(n=27,073) Serum 56% Urine 9% Both serum and urine 8% Any 76% None 24%
Pregnancy Testing Before Starting Accutane by Enrollment Year n=5,108 n=5,157 n=5,206 n=5,047 n=5,283 n=2,585
Knowledge and Compliance at Onset of Therapy1989 -1990(n=9,365)
Compliance with PPP - III Contraceptive Status, By Age
Contraceptive StatusNonsurgical Contraception by Enrollment Year
Among Nonsurgical Contraceptors, % Reporting Oral Contraceptive Use by Enrollment Year
Among Contraceptors% Reporting Use of 2+ Methods by Age Group